Research Topics
Genomes and GenesSpecies | Henricus G RuheSummaryAffiliation: Academic Medical Center Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancyHenricus G Ruhe
Program for Mood Disorders, Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Neuropsychopharmacology 34:999-1010. 2009..This is explained by the absence of significant increases of SERT occupancy by paroxetine dose escalation, despite increased paroxetine serum concentrations (ISRCTN44111488)...- Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging studyHenricus G Ruhe
Program for Mood Disorders, Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands
J Clin Psychiatry 73:451-9. 2012..We quantified functional changes in the amygdala and the related limbic-subcortical-prefrontal structures after paroxetine treatment with functional magnetic resonance imaging relative to clinical responder status... - Staging methods for treatment resistant depression. A systematic reviewHenricus G Ruhe
Program for Mood Disorders, Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
J Affect Disord 137:35-45. 2012..Treatment resistant depressant (TRD) is classified in different staging models, but these are not used routinely. We aimed to identify staging models for TRD and compare them regarding predictive utility and reliability... - Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and genderHenricus G Ruhe
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Eur J Nucl Med Mol Imaging 36:841-9. 2009..We aimed to measure SERT availability and study the effects of age, gender and season of scanning in MDD patients in comparison to healthy controls... - Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorderHenricus G Ruhe
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Pharmacogenet Genomics 19:67-76. 2009..In major depressive disorder, selective serotonin reuptake inhibitors target the serotonin transporter (SERT). Their response rates (30-50%) are modified by SERT promotor polymorphisms (5-HTTLPR)... 
Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studiesH G Ruhé
Program for Mood Disorders, Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Mol Psychiatry 12:331-59. 2007..They presumably clarify a vulnerability trait to become depressed. Directions for further investigation of this vulnerability trait are proposed...- Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic reviewHenricus G Ruhe
Department of Psychiatry, Program for Mood Disorders, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
J Clin Psychiatry 67:1836-55. 2006..For patients with insufficient response to SSRIs, switching is often applied. This article aims to systematically review the evidence for switching pharmacotherapy after a first SSRI... - Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic reviewHenricus G Ruhe
c o Mrs M Haages, Out patient Department of Psychiatry A3 255 1, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, The Netherlands
Br J Psychiatry 189:309-16. 2006..Although selective serotonin reuptake inhibitors (SSRIs) are frequently used for major depressive disorder, only 50-60% of patients respond to a standard dose. For non-responders, dose escalation is often applied... - Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scoresHenricus G Ruhe
Mentrum, Depression Research Group, Amsterdam, The Netherlands
Compr Psychiatry 46:417-27. 2005..The Maier and the Bech, two 6-item severity subscales extracted from the HDRS, are relatively unknown. This paper investigates whether the measurements obtained with these subscales are comparable with the original HDRS measurements... - Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depressionAnja Lok
Program for Mood Disorders, Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Psychoneuroendocrinology 37:892-902. 2012.... 
Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT studyMarloes J Huijbers
Department of Psychiatry, Radboud University Nijmegen Medical Center, Reinier Postlaan 10, Nijmegen 6525 GC, The Netherlands
BMC Psychiatry 12:125. 2012..abstract:..- [Dose-escalation of SSRIS in major depressive disorder. Should not be recommended in current guidelines]H G Ruhé
Universiteit van Amsterdam, Amsterdam
Tijdschr Psychiatr 52:615-25. 2010..A systematic review of the literature revealed uncertainty about the efficacy of dose escalation and pointed to methodological weaknesses in earlier research... - Tolerability of amine uptake inhibitors in urologic diseasesMartin C Michel
Dept of Pharmacology and Pharmacotherapy, Academic Medical Centre, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
Curr Drug Saf 1:73-85. 2006..Their most common side effect is nausea. However, nausea tends to be mild and, importantly, transient. Patient counselling about side effects and up-titrating doses may be useful strategies for minimising discomfort and withdrawals... - Prevalence of psychiatric disorders in patients with chronic solvent induced encephalopathy (CSE)Ieke Visser
Program for Mood Disorders, Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands
Neurotoxicology 32:916-22. 2011..This study was designed to establish the prevalence rates of DSM IV mood, anxiety, and alcohol and substance related disorders in patients with CSE... - Statistical methodological issues in handling of fatty acid data: percentage or concentration, imputation and indicesRoel J T Mocking
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Meibergdreef 5, Amsterdam 1105 AZ, The Netherlands
Lipids 47:541-7. 2012.... - Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphismN Abdelmalik
Program for Mood Disorders, Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
J Thromb Haemost 6:2168-74. 2008..Selective serotonin reuptake inhibitors (SSRIs) have been associated with an increased bleeding tendency... - Screening for depression in high-risk groups: prospective cohort study in general practiceKim D Baas
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Br J Psychiatry 194:399-403. 2009..Currently only about half of the people who have major depressive disorder are detected during regular health care. Screening in high-risk groups might be a possible solution... - Investigating serotonergic function using positron emission tomography: overview and recent findingsD J Veltman
Department of Psychiatry, Academic Medical Center, Amsterdam The Netherlands
Curr Pharm Des 16:1979-89. 2010..In the present review, an overview of recent findings is provided, and possibilities for further research are discussed...